Jefferies Financial Group Inc. hired Tim Kerry from Barclays Plc as the bank builds up its ranks to prepare for a wave of M&A-related financings.

Dallas police report the "unexplained death" of Jefferies investment banker Carter McIntosh, 28. An investigation is ongoing.

NextEra Energy (NYSE:NEE – Get Free Report) had its price target lowered by research analysts at Jefferies Financial Group from $81.00 to $77.00 in a research report issued on Monday. Jefferies Financial Group’s price objective would indicate a potential upside of 9.

Barclays has recently reduced Public Service Enterprise Group Inc (PEG) stock to Equal Weight rating, as announced on January 27, 2025, according to Finviz. Earlier, on September 13, 2024, Jefferies had initiated the stock to Hold,

In a report released today, James Rowland Clark from Barclays maintained a Buy rating on SSP Group plc (SSPG – Research Report), with a price

Investing.com -- Nextracker Inc. was upgraded by both Barclays (LON: BARC) and Jefferies on Wednesday, as analysts expressed renewed confidence in the company’s execution, margin profile, and growth potential. Jefferies upgraded Nextracker to Buy, raising its price target to $56, citing strong margins and record bookings.

W. R. Berkley (NYSE:WRB – Free Report) had its target price hoisted by Barclays from $50.00 to $52.00 in a research report released on Tuesday,Benzinga reports. They currently have an underweight rating on the insurance provider’s stock.

WEC Energy Group Inc (WEC) stock saw a decline, ending the day at $98.92 which represents a decrease of $-1.96 or -1.94% from the prior close of $100.88. The stock opened at $100.51 and touched a low of $98.

Barclays (LON:BARC) reaffirmed its positive stance on Replimune Group (NASDAQ:REPL), maintaining an Overweight rating and a $17.00 price target, representing significant upside from the current price of $11.

In a report released today, Jonathan Hurn from Barclays maintained a Hold rating on Smiths Group plc (SMIN – Research Report), with a price

JetBlue's new premium credit card comes with a hefty annual fee, but the perks might make it worthwhile for frequent flyers.

Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the company announced results from Phase 2 trials of sirexatamab in colorectal cancer and gastric cancer.